22.75

2.27% -0.195

Immunome Inc (IMNM)

Overview News Price History Option Chain Financials Discussions Forecast

Immunome Inc stock is traded at $22.75, with a volume of 10,448. It is down -2.27% in the last 24 hours and up +2.66% over the past month. Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Previous Close:

$22.94

Open:

$22.42

24h Volume:

10,448

Relative Volume:

0.01

Market Cap:

$2.57B

Revenue:

$6.94M

Net Income/Loss:

$-212.39M

P/E Ratio:

-9.3678

EPS:

-2.428

Net Cash Flow:

$-200.60M

1W Performance:

-4.56%

1M Performance:

+2.66%

6M Performance:

+45.49%

1Y Performance:

+153.33%

1-Day Range:

$22.38

$22.70

1-Week Range:

$22.16

$23.84

52-Week Range:

$7.15

$27.65

Immunome Inc Stock (IMNM) Company Profile

Name

Immunome Inc

Sector

Healthcare (1112)

Industry

Biotechnology (622)

Phone

610-321-3700

Address

18702 N. CREEK PARKWAY, BOTHELL

Employee

177

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

IMNM's Discussions on Twitter

Compare IMNM vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMNM Immunome Inc	22.70	2.57B	6.94M	-212.39M	-200.60M	-2.428
VRTX Vertex Pharmaceuticals Inc	425.25	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.98	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	788.73	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.24	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	294.41	32.66B	5.36B	287.73M	924.18M	2.5229

Immunome Inc Stock (IMNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-12-26	Initiated	H.C. Wainwright	Buy
Dec-01-25	Initiated	Truist	Buy
Sep-22-25	Initiated	Goldman	Buy
Sep-05-25	Initiated	Craig Hallum	Buy
Apr-02-25	Initiated	Lake Street	Buy
Nov-08-24	Initiated	Stephens	Overweight
May-31-24	Initiated	Piper Sandler	Overweight
Apr-30-24	Initiated	JP Morgan	Overweight
Apr-15-24	Initiated	Guggenheim	Buy
Jan-29-24	Initiated	Leerink Partners	Outperform
Dec-19-23	Initiated	Wedbush	Outperform
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight

View All

Immunome Inc Stock (IMNM) Latest News

May 02, 2026

Why (IMNM) Price Action Is Critical for Tactical Trading - Stock Traders Daily

May 02, 2026

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Immunome (IMNM) and Resmed (RMD) - The Globe and Mail

May 02, 2026

May 01, 2026

Lake Street Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $30 - Moomoo

May 01, 2026

Apr 30, 2026

Universal Beteiligungs und Servicegesellschaft mbH Acquires New Position in Immunome, Inc. $IMNM - MarketBeat

Apr 30, 2026

Apr 29, 2026

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors - BioSpace

Apr 29, 2026

Immunome (IMNM) Submits NDA for Varegacestat to Treat Desmoid Tu - GuruFocus

Apr 29, 2026

Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo

Apr 29, 2026

Immunome submits drug application for desmoid tumor treatment - Investing.com

Apr 29, 2026

Immunome submits drug application for desmoid tumor treatment By Investing.com - Investing.com Canada

Apr 29, 2026

The Bull Case For Immunome (IMNM) Could Change Following Varegacestat’s ASCO 2026 Spotlight And NDA Timeline – Learn Why - simplywall.st

Apr 25, 2026

A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing - Yahoo Finance

Apr 25, 2026

Apr 24, 2026

[ARS] Immunome Inc. SEC Filing - Stock Titan

Apr 24, 2026

Immunome (IMNM) 2026 proxy: trial success, executive pay and key stockholder votes - Stock Titan

Apr 24, 2026

Immunome Desmoid Tumor Data And NDA Plan Test Growth Expectations - simplywall.st

Apr 24, 2026

Apr 23, 2026

Immunome (IMNM) Long-Term View | Immunome Inc. 23.8% EPS Miss, No Revenue EstimateMiss Estimates - Cổng thông tin điện tử tỉnh Lào Cai

Apr 23, 2026

Apr 22, 2026

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting - BioSpace

Apr 22, 2026

Apr 21, 2026

Immunome’s desmoid tumor trial data selected for ASCO presentation By Investing.com - Investing.com Australia

Apr 21, 2026

Understanding Momentum Shifts in (IMNM) - Stock Traders Daily

Apr 21, 2026

Immunome’s desmoid tumor trial data selected for ASCO presentation - Investing.com

Apr 21, 2026

Apr 20, 2026

Immunome (IMNM) Stock: Buy, Sell, Hold? (Market Focus) 2026-04-20Turnaround Stocks - Xã Châu Thành

Apr 20, 2026

Apr 18, 2026

Is institutional money buying Immunome (IMNM) stock (+5.89%) 2026-04-18Certified Trade Ideas - UBND thành phố Hải Phòng

Apr 18, 2026

Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Immunome (IMNM) and Eli Lilly & Co (LLY) - The Globe and Mail

Apr 18, 2026

Apr 17, 2026

Piper Sandler Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛

Apr 17, 2026